Market Trends Shaping Cardiac Diabetic Pharma Franchise in India

NEW DELHI: India’s pharmaceutical industry is undergoing significant transformation, driven by the increasing prevalence of cardiovascular and diabetic diseases. According to the World Health Organization (WHO), cardiovascular disorders account for 28% of total deaths in the country, while more than 80 million adults currently suffer from diabetes – a figure projected to cross 98 million by 2025.

This growing health burden has accelerated demand for effective medications and opened up new opportunities in the pharmaceutical franchise sector, particularly in the cardiac and diabetic segment. Franchise-based models are enabling wider access to medicines, while also providing business opportunities across diverse regions in India.